Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

Inclusion Criteria: Histologically confirmed metastatic adenocarcinoma of the colon or rectum Not amenable to surgical resection Recurrent or persistent disease after standard surgery, radiotherapy, and chemotherapy, including fluorouracil and irinotecan TAG-72 positive Performance status - ECOG 0-2 WBC greater than 3,500/mm^3 Platelet count greater than 125,000/mm^3 Hemoglobin greater than 10 g/dL No nucleated RBC or significant teardrop RBC morphology Bilirubin less than 1.5 mg/dL SGOT/SGPT less than 4 times normal Hepatitis B surface antigen negative Creatinine less than 2.0 mg/dL HIV negative No other malignancy within the past 5 years except basal cell skin cancer No allergy to iodine No detectable antibody to monoclonal antibody CC49 Not pregnant or nursing Fertile patients must use effective contraception At least 3 weeks since prior immunotherapy and recovered No prior bone marrow or stem cell transplantation No other concurrent immunotherapy See Disease Characteristics At least 3 weeks since prior chemotherapy and recovered No concurrent chemotherapy See Disease Characteristics At least 3 weeks since prior radiotherapy and recovered No prior radiotherapy to more than 25% of red marrow No concurrent radiotherapy See Disease Characteristics At least 3 weeks since prior surgery and recovered